Delivery Order SPE2DR25D3301-SPE2DR26F18AX
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Tobramycin 300 mg/5 mL ampule unit dose vials, with a ceiling value of $1,042.60 and an ultimate completion date of November 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Tobramycin 300 mg/4 mL ampules with a ceiling value of $7,621.21 under firm fixed price terms. The order was competitively awarded without set-aside designation and is scheduled for completion by July 29, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Tobramycin is an aminoglycoside antibiotic commonly used to treat serious...
- The Defense Logistics Agency awarded a delivery order valued at $3,061.26 to AmerisourceBergen Drug Corp for Tobramycin 1.2 GM vials, a critical antibiotic pharmaceutical product. This contract was competitively awarded on November 5, 2025, with an ultimate completion date of November 6, 2025, and utilizes firm fixed pricing with no set-aside designation. The work will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a...
- This is a $4,134.34 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Tobramycin 300 mg/5 ml ampule in 5 ml units. The order has an ultimate completion date of April 8, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical supplies to support military...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $35,434.99 firm fixed-price delivery order is for the supply of Tobramycin 300 mg/4 ml ampules, a critical antibiotic medication. The contract has an ultimate completion date of May 15, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide Tobramycin 300 mg/5 ml ampules. The contract has a potential value of $4,188.53 and a completion date of January 31, 2024. Amerisourcebergen Drug Corp serves as a prime contractor for DLA Troop Support Medical, providing a range of pharmaceutical products and medical supplies to support military treatment programs. This...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order worth $28,502.07 to Amerisourcebergen Drug Corp, a subsidiary of parent company Cencora, Inc. The order is for the supply of 4,564,261,702 units of the medication Tobramycin 300 mg/4 ml ampules. The delivery order has an ultimate completion date of April 15, 2024. Amerisourcebergen Drug Corp, as a prime contractor, also holds an indefinite delivery contract (IDC) with DLA worth up to $999,999,999.00 through...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, the Corporate Office division of Amerisourcebergen Corporation, a major pharmaceutical distribution company. The $4,119.26 firm fixed price contract is for the supply of 4,558,749,565 units of the drug Tobramycin 300 mg/5 ml ampules. This order is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued up to $999,999,999.00...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide Tobramycin 300 mg/5 ml ampules. The contract has a potential value of $9,313.23 and a performance period through January 26, 2024. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical distribution company Amerisourcebergen Corporation. The contract is for the provision of Tobramycin 300 mg/5 ml ampules, a specialty pharmaceutical product, with a total potential value of $2,037.22. The contract has a period of performance through January 26, 2024. Amerisourcebergen Drug Corp holds a larger indefinite delivery...
- SPE2DR25D3301Indefinite Delivery Contract
- SPE2DR25D3301-SPE2DR26F18AXDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,604.14 to AmerisourceBergen Drug Corp for the supply of Tobramycin 300 mg/4 mL ampules on November 13, 2025, with completion expected by November 14, 2025. This delivery order, issued under a firm fixed-price arrangement with no set-aside designation, represents a competitively awarded transaction supporting federal pharmaceutical procurement needs. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The parent IDC enables the contractor to supply a broad range of pharmaceutical products and medical supplies supporting military healthcare programs and federal medical systems worldwide. Tobramycin, an aminoglycoside antibiotic, is a critical pharmaceutical commodity within the company's portfolio of therapeutic products delivered to support Defense Health Agency, U.S. Coast Guard, and other government healthcare system requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 11/13/25 |